Relationship between serum tumor abnormal protein and chemotherapy efficacy in patients with lung adenocarcinoma
Pages: 569-571
Year: 2017 Issue: 5
Journal: Oncology Progress
Abstract: Objective To explore the relationship between serum tumor abnormal protein (TAP) and chemotherapy efficacy in patients with lung adenocarcinoma. Method 100 cases of lung adenocarcinoma patients who had undergone postoperative adjuvant or palliative treatment (lung adenocarcinoma group) and 50 cases of healthy subjects (control group) were enrolled to compare the TAP levels prior to treatment between two groups and the TAP levels in patients be-tween different pathological stages of lung adenocarcinoma. The lung adenocarcinoma patients were grouped according to their chemotherapy efficacy to analyze the difference in TAP level before and after treatment. Result The TAP level and positive rate in lung adenocarcinoma group were both significantly higher than those in control group (P<0.01);the difference of TAP levels in patients with lung adenocarcinoma between different pathological stages were statistically sig-nificant (P<0.05), and higher TAP levels were associated with more advanced pathological stage. In complete response group and partial response group, TAP levels after treatment were lower than those before treatment. In progression group, TAP levels after treatment were higher than those before treatment, and the differences reached statistical signifi-cant (P<0.05);the worse the efficacy got, the higher the TAP level was. Conclusions The serum TAP levels in patients with lung adenocarcinoma increase significantly;TAP levels are higher in patients with more advanced disease and worse prognosis. TAP can be used as an important prognostic indicator for lung adenocarcinoma.
Year: 2017 Issue: 5
Journal: Oncology Progress
Abstract: Objective To explore the relationship between serum tumor abnormal protein (TAP) and chemotherapy efficacy in patients with lung adenocarcinoma. Method 100 cases of lung adenocarcinoma patients who had undergone postoperative adjuvant or palliative treatment (lung adenocarcinoma group) and 50 cases of healthy subjects (control group) were enrolled to compare the TAP levels prior to treatment between two groups and the TAP levels in patients be-tween different pathological stages of lung adenocarcinoma. The lung adenocarcinoma patients were grouped according to their chemotherapy efficacy to analyze the difference in TAP level before and after treatment. Result The TAP level and positive rate in lung adenocarcinoma group were both significantly higher than those in control group (P<0.01);the difference of TAP levels in patients with lung adenocarcinoma between different pathological stages were statistically sig-nificant (P<0.05), and higher TAP levels were associated with more advanced pathological stage. In complete response group and partial response group, TAP levels after treatment were lower than those before treatment. In progression group, TAP levels after treatment were higher than those before treatment, and the differences reached statistical signifi-cant (P<0.05);the worse the efficacy got, the higher the TAP level was. Conclusions The serum TAP levels in patients with lung adenocarcinoma increase significantly;TAP levels are higher in patients with more advanced disease and worse prognosis. TAP can be used as an important prognostic indicator for lung adenocarcinoma.
Related Articles